Silence reports Phase 1 data from rare blood disorder trial

Max Gelman

Senior Editor

Silence Therapeutics touted Phase 1 data from an ongoing study Thursday morning in patients with a rare disease where their bone marrow produces too many …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Silence reports Phase 1 data from rare blood disorder trial

Max Gelman

Senior Editor

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO

Si­lence re­ports Phase 1 da­ta from rare blood dis­or­der tri­al

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

Silence reports Phase 1 data from rare blood disorder trial

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO